Hepatitis C

Hepatitis C is a viral infection caused by the hepatitis C virus (HCV) — a single-stranded RNA virus that primarily infects liver cells, using them as factories to replicate. Unlike hepatitis B, there is no vaccine against hepatitis C. Unlike hepatitis A, it commonly establishes a chronic, persistent infection rather than resolving on its own.

HCV exists in seven major genotypes numbered 1 through 7 with numerous subtypes within each. Genotype distribution varies geographically: genotype 1 is most prevalent in Europe and North America, genotype 3 in South Asia, and genotypes 4 through 6 are predominant in Africa, the Middle East, and East Asia. Genotype matters for treatment decisions, though the newest generation of antiviral drugs is effective across all genotypes — a development that has simplified treatment enormously.

When a person is exposed to HCV, the immune system attempts to clear it. In approximately 25 to 30 percent of acutely infected individuals mostly younger people with robust immune responses the immune system succeeds, and the virus is eliminated spontaneously within six months. In the remaining 70 to 75 percent, the virus evades immune clearance and establishes a chronic infection that persists indefinitely without treatment.

Chronic hepatitis C drives a slow, progressive process of liver inflammation and fibrosis. The timeline is long significant liver damage typically takes 20 to 30 years to develop but it is relentless without intervention. Understanding this timeline explains both why hepatitis C is so often missed (there are no symptoms for decades) and why treatment is so important even in people who currently feel completely well.

Hepatitis C has a well-earned reputation as a silent disease. For most people, the infection produces no symptoms at all during the acute phase or symptoms so mild and non-specific that they are attributed to stress, a minor virus, or simply feeling under the weather.

Acute hepatitis C — the initial infection is symptomatic in only about 20 to 30 percent of people. When symptoms do occur, they typically appear two to twelve weeks after exposure and include fatigue, nausea, loss of appetite, mild abdominal discomfort, and occasionally mild jaundice. These symptoms are indistinguishable from dozens of other minor illnesses and rarely prompt specific testing for hepatitis C.

Chronic hepatitis C — the persistent infection is asymptomatic for the majority of its course. Most people feel entirely normal for years or decades. When symptoms do emerge, they tend to be vague and easily dismissed: persistent fatigue that does not improve with rest, mild cognitive difficulties sometimes described as "brain fog," and a general sense of not feeling quite right that is hard to articulate.

As liver disease progresses toward significant fibrosis and eventually cirrhosis, more specific and disabling symptoms emerge. These include progressive fatigue and weakness, loss of appetite, unintentional weight loss, abdominal swelling from fluid accumulation (ascites), jaundice yellowing of the skin and eyes and easy bruising or bleeding due to impaired clotting factor production.

Extrahepatic manifestations — symptoms affecting organs outside the liver occur in a significant minority of people with chronic hepatitis C and are often overlooked as being related to the infection. These include mixed cryoglobulinaemia (an immune complex disorder causing rash, joint pain, and kidney problems), membranoproliferative glomerulonephritis (kidney inflammation), lichen planus (a skin and mucous membrane condition), thyroid abnormalities, and an increased risk of type 2 diabetes and non-Hodgkin lymphoma.

The critical implication of this symptom pattern is clear: waiting for symptoms before seeking testing means waiting until the disease has already caused significant damage. Testing based on risk factors not symptoms is the appropriate trigger.

Hepatitis C is transmitted through blood-to-blood contact. Unlike hepatitis B, it is not efficiently transmitted through sexual contact or from mother to child, though these routes are possible in specific circumstances.

Injecting drug use is the dominant route of transmission in high-income countries, accounting for the majority of new infections. Sharing needles, syringes, spoons, water, filters, or any other injecting equipment with an infected person carries significant transmission risk. HCV is highly resilient — it can survive in a used syringe for up to six weeks at room temperature.

Healthcare-associated transmission — through contaminated medical equipment, inadequately sterilised instruments, or needlestick injuries — remains a significant route in countries with limited healthcare resources and blood safety infrastructure. Healthcare workers in all settings face occupational exposure risk through needlestick injuries.

Blood transfusion and blood products were major transmission routes before HCV was identified in 1989 and blood supplies began to be screened. People who received transfusions or blood products before the mid-1990s in high-income countries — and before equivalent screening was implemented in lower-income countries — remain at elevated risk of undiagnosed infection.

Tattooing and body piercing with non-sterile equipment carry transmission risk, particularly in unregulated settings where ink may be shared or equipment inadequately sterilised between clients.

Nosocomial transmission — within healthcare settings — through reused or inadequately sterilised endoscopes, dialysis equipment, or multi-dose medication vials has been documented in outbreak settings.

Sexual transmission of hepatitis C is possible but substantially less efficient than for hepatitis B or HIV. The risk is low in heterosexual monogamous relationships but higher with practices that increase blood exposure — anal sex, concurrent sexually transmitted infections, or multiple partners. Men who have sex with men, particularly those with HIV co-infection, face a meaningful sexual transmission risk.

Perinatal transmission — from mother to infant during childbirth — occurs in approximately 5 to 6 percent of pregnancies where the mother has active HCV infection (detectable viral load). The risk is higher in HIV co-infected mothers.

Hepatitis C is not transmitted through casual contact — hugging, shaking hands, sharing food or drinks, coughing, sneezing, or using the same toilet facilities.

Understanding personal risk factors is the most practical way to identify who needs testing — because risk-based testing catches hepatitis C long before symptoms develop.

Current or past injecting drug use is the strongest single risk factor even a single episode of sharing injecting equipment decades ago carries meaningful exposure risk. People who have ever injected drugs, regardless of how long ago, should be tested.

Receipt of blood transfusions, organ transplants, or blood products before 1992 in high-income countries when screening of blood supplies for HCV became standard represents a historical exposure risk that has led to a cohort of older adults with long-standing undiagnosed infection.

Being born between 1945 and 1985 the "baby boomer" generation is associated with disproportionately high HCV prevalence in many countries, reflecting historical exposure before widespread blood screening and harm reduction programmes.

Healthcare work with potential exposure to blood through needlestick injuries or blood splashes creates ongoing occupational risk.

Haemodialysis — long-term kidney dialysis is associated with elevated risk due to repeated vascular access and shared equipment.

Having HIV infection significantly increases hepatitis C risk due to overlapping transmission routes and increases the rate of liver fibrosis progression in co-infected individuals.

Incarceration is associated with elevated HCV prevalence due to the concentration of people with injecting drug use histories and limited access to harm reduction in prison settings.

Being born to an HCV-positive mother creates a perinatal exposure risk.

People with multiple sexual partners or a history of sexually transmitted infections have modestly elevated risk.

The complications of untreated chronic hepatitis C are serious, progressive, and predominantly liver-related — though extrahepatic consequences are also clinically significant.

Liver fibrosis is the fundamental process driving all liver complications. Chronic HCV-induced inflammation leads to activation of hepatic stellate cells, which deposit collagen in the liver. Over time, this fibrosis accumulates from mild (stage 1) through moderate (stage 2) and advanced (stage 3) to cirrhosis (stage 4). The rate of progression varies between individuals — influenced by age at infection, sex, alcohol consumption, obesity, co-infection with HIV or HBV, and genetic factors.

Cirrhosis develops in approximately 15 to 30 percent of people with untreated chronic hepatitis C over 20 to 30 years. Once cirrhosis is present, the risk of further complications rises substantially and the trajectory of disease accelerates.

Hepatocellular carcinoma — liver cancer — develops in one to five percent of cirrhotic patients per year. HCV-related liver cancer is one of the most common and serious complications of the infection and is a major cause of liver cancer mortality worldwide. Achieving a cure through antiviral treatment dramatically reduces — but does not entirely eliminate — the risk of liver cancer in patients who already have cirrhosis, which is why surveillance continues even after cure.

Portal hypertension and its consequences — ascites, oesophageal varices, and hepatic encephalopathy — develop in patients with advanced cirrhosis and significantly worsen quality of life and prognosis.

Liver failure is the end-stage outcome of progressive, uncontrolled cirrhosis — characterised by jaundice, coagulopathy, encephalopathy, and kidney dysfunction — and may ultimately require liver transplantation.

Extrahepatic complications include mixed cryoglobulinaemia vasculitis, kidney disease, lymphoma, insulin resistance and type 2 diabetes, cardiovascular disease, and cognitive impairment. These complications can cause significant morbidity independently of liver disease severity and, importantly, many of them improve or resolve after successful Hepatitis C treatment.

Diagnosing hepatitis C is a two-step process — first establishing whether the person has been exposed to the virus, then confirming active infection.

Anti-HCV antibody test is the initial screening test. It detects antibodies that the immune system produces in response to HCV infection. A positive result indicates exposure to hepatitis C at some point — but not necessarily active current infection, because antibodies persist even after the infection has been cleared (either spontaneously or through treatment). The antibody test becomes positive within eight to twelve weeks of infection in most people.

HCV RNA (viral load) test is the confirmatory test. It directly detects and quantifies the actual virus in the blood. A positive HCV RNA confirms active, ongoing infection. A negative HCV RNA in a person with positive antibodies indicates either spontaneous viral clearance or successful prior treatment. HCV RNA testing is also used to monitor treatment response — it becomes undetectable within weeks of starting effective antiviral therapy in most patients.

HCV genotype testing identifies which of the seven major genotypes of the virus is present. While pan-genotypic treatments have reduced the clinical urgency of genotyping, it remains relevant in certain treatment decisions and resistance assessment scenarios.

Liver fibrosis assessment is performed to stage the degree of liver damage before treatment. This is done non-invasively using FibroScan (transient elastography), which measures liver stiffness as a proxy for fibrosis, or through serum fibrosis marker panels. Liver biopsy — once the gold standard — is now rarely performed for staging purposes in routine hepatitis C management.

Liver function tests — ALT, AST, bilirubin, albumin, and INR — assess liver synthetic function and the degree of ongoing inflammation.

Additional tests include full blood count (looking for thrombocytopenia from portal hypertension), kidney function, HIV and hepatitis B co-infection screening, and liver ultrasound for baseline assessment and hepatocellular carcinoma screening in cirrhotic patients.

Treatment of Hepatitis C has undergone a revolution that few areas of medicine can match. The introduction of direct-acting antiviral (DAA) drugs in the mid-2010s transformed a difficult, poorly tolerated, and often ineffective treatment into a short, well-tolerated, oral regimen that cures the vast majority of patients.

Direct-Acting Antiviral Drugs (DAAs)

DAAs work by targeting specific proteins the hepatitis C virus needs to replicate. There are three main classes, targeting different stages of the viral replication cycle.

NS3/4A protease inhibitors block the viral protease enzyme responsible for processing the hepatitis C polyprotein into functional components. Drugs in this class include grazoprevir, voxilaprevir, and glecaprevir.

NS5A inhibitors block the NS5A protein, which is essential for viral replication and assembly. Ledipasvir, velpatasvir, elbasvir, and pibrentasvir are the key drugs in this class.

NS5B polymerase inhibitors block the enzyme the virus uses to copy its RNA. Sofosbuvir is the most important drug in this class and has become the backbone of most treatment regimens.

Current First-Line Treatment Regimens

The most widely used treatment regimens are fixed-dose combination tablets that combine drugs from different classes to achieve maximum viral suppression.

Sofosbuvir/velpatasvir (Epclusa) is a pan-genotypic regimen — effective against all HCV genotypes — given as one tablet daily for 12 weeks. It achieves sustained virological response rates (the definition of cure) of 95 to 99 percent across genotypes in patients without cirrhosis.

Glecaprevir/pibrentasvir (Maviret) is another pan-genotypic combination given as three tablets daily. Its key advantage is an eight-week treatment duration for treatment-naive patients without cirrhosis — one of the shortest available courses. It achieves cure rates of 97 to 99 percent in this population.

Sofosbuvir/ledipasvir (Harvoni) is used primarily for genotype 1 infection and remains widely available, with cure rates exceeding 95 percent.

Treatment duration depends on the regimen chosen, the patient's prior treatment history, the presence or absence of cirrhosis, and the genotype. Most patients are treated for 8 to 12 weeks. Patients with decompensated cirrhosis or prior treatment failure may require 16 to 24 weeks and additional drugs.

Sustained Virological Response (SVR)

The goal of Hepatitis C treatment is sustained virological response — defined as undetectable HCV RNA in the blood 12 weeks after completing treatment. SVR is considered a functional cure. The virus does not reappear after SVR is achieved — patients who achieve it are considered permanently cured of hepatitis C. SVR is associated with regression of liver fibrosis, dramatically reduced risk of cirrhosis and liver cancer, resolution of many extrahepatic manifestations, and improved quality of life.

Treatment of Hepatitis C in special populations requires particular consideration. Patients with decompensated cirrhosis are generally treated with interferon-free, ribavirin-free regimens and may need sofosbuvir/velpatasvir with ribavirin for 12 weeks. Patients co-infected with HIV can be treated with the same DAA regimens, with attention to drug-drug interactions with antiretroviral therapy. Patients with kidney disease, including those on haemodialysis, can now be treated safely with glecaprevir/pibrentasvir, which does not require dose adjustment for renal impairment.

Monitoring During Treatment

HCV RNA is tested at baseline, at treatment completion, and 12 weeks after completion to confirm SVR. Liver function tests are monitored periodically. Drug interactions — particularly with acid-suppressing medications, statins, and certain cardiac drugs — are reviewed carefully before treatment initiation and managed where necessary.

You should seek medical evaluation for hepatitis C without waiting for symptoms — because by the time symptoms appear, significant liver damage may have already occurred.

See your healthcare provider if you have any of the following risk factors: you have ever injected drugs, even once; you received a blood transfusion or organ transplant before 1992; you have been on long-term haemodialysis; you have HIV infection; you were born to an HCV-positive mother; you work in healthcare and have had a needlestick or blood splash injury; you have had a tattoo or piercing in a non-sterile environment; or you were born between 1945 and 1985 and have never been tested.

See your provider promptly if blood tests done for any reason show abnormal liver function results — elevated ALT or AST — as these may indicate hepatitis C or another liver condition requiring investigation.

Seek urgent medical attention if you develop any of the following symptoms, which may indicate advanced liver disease: sudden onset jaundice, significant abdominal swelling, confusion or disorientation, vomiting blood, or passing very dark or tarry stools. These are signs of serious liver decompensation requiring immediate hospital assessment.

Unlike hepatitis A and B, there is no vaccine against hepatitis C. Prevention therefore relies entirely on reducing exposure to infected blood.

Harm reduction for people who inject drugs is the single most impactful prevention strategy for new HCV transmission globally. Needle and syringe programmes that provide sterile injecting equipment, supervised consumption facilities, and opioid substitution therapy have been shown to dramatically reduce new HCV infections in communities where they are implemented comprehensively.

Never sharing injecting equipment — needles, syringes, spoons, water, filters, or any paraphernalia — is the core message for people who inject drugs. Each item used only once and never shared eliminates the blood-to-blood contact that transmits the virus.

Universal precautions in healthcare — using personal protective equipment, disposing of sharps safely, never recapping needles, and following established infection control protocols — protect healthcare workers from occupational exposure and prevent patient-to-patient transmission.

Screening of blood and organ donations for HCV antibodies and RNA is standard practice in high-income countries and has made transfusion-related transmission extremely rare. Advocacy for equivalent screening standards in lower-income countries remains an important global health priority.

Safe tattooing and piercing — using sterile, single-use equipment and properly sterilised or disposable needles — eliminates transmission risk in these settings. Seeking reputable, regulated practitioners is advisable.

Post-exposure management after needlestick injuries in healthcare workers involves HCV RNA testing of the source patient (if identifiable) and baseline and follow-up testing of the exposed worker. Unlike hepatitis B, there is no post-exposure prophylaxis available for hepatitis C — but early identification of infection, if it occurs, allows prompt treatment before chronic infection is established.

Treatment as prevention is an increasingly important concept. Curing hepatitis C in infected individuals removes them from the pool of potential transmission sources — contributing to population-level reductions in new infections. Expanding access to Hepatitis C treatment is therefore not only a clinical imperative but a public health one.

Hepatitis C is a disease that medicine has genuinely conquered — at least in terms of individual cure. The Treatment of Hepatitis C available today is safe, short, effective, and accessible to more people than at any previous point in history. A virus that was discovered only in 1989, that caused widespread liver disease and death for decades, and that resisted effective treatment for so long, can now be eliminated from the body in eight to twelve weeks with a daily tablet and minimal side effects.

What remains is the gap between what is medically possible and what is actually achieved. Millions of people around the world are living with hepatitis C without knowing it undiagnosed, untreated, accumulating liver damage that could be stopped. Reaching those people requires better awareness, broader testing, reduced stigma around the risk factors most commonly associated with the infection, and continued expansion of treatment access.

If you have risk factors for hepatitis C, the most important thing you can do is get tested. If you test positive, the most important thing you can do is begin Hepatitis C treatment without delay. The treatment works. The cure is real. And the liver damage that hepatitis C causes while serious can be halted, and in many cases partially reversed, when the virus is eliminated. The era of untreatable hepatitis C is over. What is needed now is to ensure that the people who need this cure actually receive it.